Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter
Article first published online: 13 DEC 2005
Alimentary Pharmacology & Therapeutics
Volume 23, Issue 1, pages 129–135, January 2006
How to Cite
HUANG, Y.-H., WU, J.-C., CHEN, S.-C., CHEN, C.-H., CHIANG, J.-H., HUO, T.-I., LEE, P.-C., CHANG, F.-Y. and LEE, S.-D. (2006), Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Alimentary Pharmacology & Therapeutics, 23: 129–135. doi: 10.1111/j.1365-2036.2006.02704.x
- Issue published online: 13 DEC 2005
- Article first published online: 13 DEC 2005
- Publication data Submitted 17 June 2005 First decision 8 July 2005 Resubmitted 8 September 2005 Resubmitted 26 September 2005 Accepted 1 October 2005
The safety and survival benefit of transcatheter arterial chemoembolization for patients with huge hepatocellular carcinoma is uncertain.
To evaluate the role of embolization in unresectable hepatocellular carcinomas larger than 10 cm.
Twenty-six consecutive patients who had an unresectable hepatocellular carcinoma larger than 10 cm and refused aggressive treatment, were enrolled as the control group. Another 31 patients matching with the control cases and undergoing embolization for huge unresectable hepatocellular carcinoma served as the embolization group. Survival between the two groups was compared.
Two patients (7%) died from embolization-related complications. Patients in embolization group had longer survival than those in control group (median survival: 9.13 vs. 2.1 months). The 1-, 3- and 5-year survival rates in embolization group were 42%, 13% and 7% respectively. The 1- and 3-year survival rates for patients in control group were 8% and 0% respectively. In multivariate analysis, embolization and prothrombin ratio ≤1.2 were two independent factors associated with a better survival.
Embolization-related mortality is low for huge hepatocellular carcinoma, and the technique provides survival benefit in patients with unresectable hepatocellular carcinomas larger than 10 cm in diameter.